In the CheckMate 012 study, patients with advanced NSCLC were treated with a combination of nivolumab and ipilimumab, and excellent response rates were documented in patients with PD-L1-positive tumors [422,423]. Here, CD274 is linked to non-small cell lung carcinoma.